Stockwatch: The integrity of the life sciences market
This article was originally published in Scrip
Executive Summary
This current earnings season is accompanied by a UK general election, in which the leaders of the three largest parties were last week ridiculed by members of the public during a televised debate for having lost their trust. UK politicians have presented the electorate with expenses scandals, broken promises and much worse, with the result that we no longer believe anything they say. They have lost their integrity.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.